CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation

Protein kinase CK2 - formerly referred to as casein kinase II - is a serine/threonine kinase often found overexpressed in solid tumors and hematologic malignancies that phosphorylates many substrates integral to the hallmarks of cancer. CK2 has emerged as a viable oncology target having been experimentally validated with different kinase inhibitors including small molecule ATP-competitors, synthetic peptides and antisense oligonucleotides. To date only two CK2 inhibitors, CIGB-300 and CX-4945, have entered the clinic in Phase 1-2 trials.

Source: Seminars in Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Silvio E. Perea, Idania Baladr ón, Carmen Valenzuela, Yasser Perera Source Type: research